- Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
-
Yagisawa K, Kobayashi T, Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida M, Saito E, Nakano M, Matsubara H, Hisamatsu T, Hibi T
- KMID: 2504591
- Intest Res.
- 2020 Jul;18(3):343-344.
- doi: 10.5217/ir.2018.00078-c1
-
- CITED
-
- Close
- SHARE
-
- Close
- Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
-
Okabayashi S, Kobayashi , Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T
- KMID: 2449963
- Intest Res.
- 2019 Apr;17(2):218-226.
- doi: 10.5217/ir.2018.00117
BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range... -
- CITED
-
- Close
- SHARE
-
- Close
- Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
-
Sakurai K, Furukawa S, Katsurada T, Otagiri S, Yamanashi K, Nagashima K, Onishi R, Yagisawa K, Nishimura H, Ito T, Maemoto A, Sakamoto N
- KMID: 2525075
- Intest Res.
- 2022 Jan;20(1):78-89.
- doi: 10.5217/ir.2020.00124
Background/Aims: Inflammatory bowel disease (IBD) patients frequently have zinc deficiency. IBD patients with zinc deficiency have higher risks of IBD-related hospitalization, complications, and requiring surgery. This study aimed to examine... -
- CITED
-
- Close
- SHARE
-
- Close
- Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
-
Yagisawa K, Kobayashi , Ozaki R, Okabayashi S, Toyonaga T, Miura M, Hayashida , Saito E, Nakano M, Matsubara , Hisamatsu , Hibi T
- KMID: 2438447
- Intest Res.
- 2019 Jan;17(1):87-93.
- doi: 10.5217/ir.2018.00078
BACKGROUND/AIMS: Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The... -
- CITED
-
- Close
- SHARE
-
- Close
